Document is current

Article History

Received: 17 December 2022

Accepted: 3 February 2023

First Online: 16 February 2023

Declarations

:

: The study design was approved by the loca ethics committee (Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster). The study was conducted in accordance with the Declaration of Helsinki.

: Not applicable as no individual person’s data is included.

: BL has received a grant from the medical faculty Münster, was involved in a study funded by Clexio Biosciences Ltd and received honoraria from the DGM e.V. for a lecture; AJ has nothing to disclose; SA has nothing to disclose; SO: has nothing to disclose; PM: has nothing to dsiclose; MR: has nothing to disclose; FW: has nothing to disclose; JVI: has nothing to disclose; IC has previously received honoraria from Abbvie, BIAL, STADAPHARM, Georg Thieme Verlag KG, and consultancies from STADAPHARM and was involved in a study funded by Clexio Biosciences Ltd.; TW reports advisory board memberships for AbbVie, UCB, Archimedes, Phagenesis, Zambon, Bial, Kyowa, honoraria for lectures from Bial, AbbVie, STADA, UCB, Biogen, Licher, Desitin, Pfizer, Zambon, Teva, Bayer, Grants (investigator-initiated) from UCB, Licher, Abbvie and Clexio Biosciences Ltd., academic grants from G-BA Innovation Fund, Deutsche Parkinson-Vereinigung (dPV), IZKF, Neuro NRW; RD reports non-financial support from Phagenesis, personal fees from Nestle Healthcare, grants from Olympus, personal fees from Sanofi, personal fees from Pfizer, personal fees from Daiichi Sankyo, outside the submitted work, SSK was supported by the Else Kröner-Fresenius-Stiftung with a clinician scientist endowed professorship.